HGS stock skyrockets on Glaxo deal talk

Talk is once again raging that GlaxoSmithKline is negotiating to buy Human Genome Sciences for some $4 billion. HGS, which makes an experimental lupus drug, saw its stock soar for the sixth straight day on rumors that Glaxo might make a $30-per-share-offer. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.